ADMA
ADMA Biologics Inc
NASDAQ: ADMA · HEALTHCARE · BIOTECHNOLOGY
$9.38
-1.47% today
Updated 2026-09-25
Market cap
$2.20B
P/E ratio
14.01
P/S ratio
4.29x
EPS (TTM)
$0.70
Dividend yield
—
52W range
$7 – $20
Volume
2.6M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B8.5
Quality
A10.0
Profitability
A+6.0
Valuation
B4/9
Piotroski F-Score
Moderate
4.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →261 stocks currently score above 75
Price targets
Analyst target
$17.00
+81.24%
12-Month target
$9.58
+2.13%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.17 — safe zone
+ Profit margin 33.00% — above average
+ ROE 42.36% — strong efficiency
+ Free cash flow $27.28M — positive
+ Debt/equity 0.50x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $154.08M | $258.21M | $426.45M | $510.17M | $512.27M |
| Net income | $-65.90M | $-28.24M | $197.67M | $146.93M | $37.82M |
| EPS | — | — | — | — | $0.70 |
| Free cash flow | $-73.42M | $3.82M | $110.10M | $27.82M | $27.28M |
| Profit margin | -42.77% | -10.94% | 46.35% | 28.80% | 33.00% |
Peer comparison
Smart narrative
ADMA Biologics Inc trades at $9.38. representing a P/E of 14.01x trailing earnings. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 4.17, it sits in the safe zone. TTM revenue stands at $512.27M. with profit margins at 33.00%.
Frequently asked questions
What is ADMA Biologics Inc's stock price?
ADMA Biologics Inc (ADMA) trades at $9.38, on a P/E of 14.0x and a P/S of 4.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is ADMA Biologics Inc overvalued?
ADMA Biologics Inc carries a Smart Value Score of 58/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of ADMA Biologics Inc (ADMA)?
The 12-month analyst consensus target is $17.00, about 81.2% above the current $9.38. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is ADMA Biologics Inc's revenue?
ADMA Biologics Inc's trailing twelve-month revenue is $512.27M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
ADMA Biologics Inc's Altman Z-Score is 4.17, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.29x
ROE42.36%
Beta0.77
50D MA$9.20
200D MA$12.20
Shares out0.22B
Float0.22B
Short ratio—
Avg volume2.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—